CIK 0000873303 · Large accelerated filer
Sarepta Therapeutics, Inc.
Sign in to watch- Ticker
- SRPT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 930797222
- Phone
- 617-274-4000
- Business address
- 215 FIRST STREET, SUITE 415, CAMBRIDGE, MA, 02142
- Former names
- Sarepta Therapeutics, Inc., AVI BIOPHARMA INC, ANTIVIRALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-26 | Estepan Ian Michael Chief Operating Officer | Option exercise · Stock Option (right to buy) | −5,381 | 0 | ||
| 2026-02-25 | Estepan Ian Michael Chief Operating Officer | Grant or award · Performance Stock Units | +1,875 | 8,125 | ||
| 2026-02-25 | Rodino-Klapac Louise President, R&D and Tech Ops | Grant or award · Performance Stock Units | +1,875 | 8,125 | ||
| 2026-01-29 | Nicaise Claude Director | Option exercise | +10,500 | $13.71 | $144K | 38,312 |
| 2026-01-29 | Nicaise Claude Director | Shares withheld for taxes | −6,780 | $21.23 | $144K | 31,532 |
| 2026-01-29 | Nicaise Claude Director | Option exercise · Stock Option (right to buy) | −10,500 | 0 | ||
| 2026-01-27 | BEHRENS M KATHLEEN Director | Option exercise | +10,500 | $13.71 | $144K | 203,976 |
| 2026-01-27 | BEHRENS M KATHLEEN Director | Shares withheld for taxes | −6,494 | $22.17 | $144K | 197,482 |
| 2026-01-27 | BEHRENS M KATHLEEN Director | Option exercise · Stock Option (right to buy) | +10,500 | 0 | ||
| 2025-12-18 | Chambers Michael Andrew Director | Returned to the company · Convertible Senior Notes | −0 | |||
| 2025-12-18 | Chambers Michael Andrew Director | Grant or award · Convertible Senior Notes | +0 | |||
| 2025-12-16 | Estepan Ian Michael Chief Operating Officer | Sale | −13,187 | $22.31 | $294K | 193,300 |
| 2025-12-07 | INGRAM DOUGLAS S Chief Executive Officer | Grant or award | +50,000 | 440,307 | ||
| 2025-12-07 | INGRAM DOUGLAS S Chief Executive Officer | Grant or award | +50,000 | 490,307 | ||
| 2025-12-07 | INGRAM DOUGLAS S Chief Executive Officer | Grant or award | +73,001 | 563,308 | ||
| 2025-12-07 | INGRAM DOUGLAS S Chief Executive Officer | Grant or award | +96,541 | 659,849 | ||
| 2025-12-07 | INGRAM DOUGLAS S Chief Executive Officer | Grant or award | +269,542 | 929,391 | ||
| 2025-12-01 | Wong Ryan Ho-Yan Chief Financial Officer | Shares withheld for taxes | −80 | $20.96 | $2K | 136,123 |
| 2025-12-01 | Wong Ryan Ho-Yan Chief Financial Officer | Shares withheld for taxes | −78 | $20.96 | $2K | 136,045 |
| 2025-11-28 | Rothfuss Cristin EVP, General Counsel | Shares withheld for taxes | −229 | $21.12 | $5K | 139,756 |
Page 3 of 12 · 227 trades